Evaluating CAR-T Cognitive Outcomes (ECCO) study
Research type
Research Study
Full title
Evaluating CAR-T Cognitive Outcomes (ECCO) study
IRAS ID
321095
Contact name
Robin Sanderson
Contact email
Sponsor organisation
The R&I Office, Research & Innovation Governance Manager
Duration of Study in the UK
3 years, 0 months, 1 days
Research summary
CAR-T is a new treatment for blood cancers that involves reprogramming the patient's own white blood cells to attack their cancer. A well-known short-term side-effect of CART is neurological impairment, which seems to resolve after a week. However it is not known if milder cognition problems persist after this early phase. This study will use longitudinal assessment of cognition for 12 months following treatment with CAR-T in order to identify any persistent cognitive impairment and other data from routine clinical assessments will be explored as potential predictors of cognitive problems. This will allow us to identify unmet neuropsychological needs in this group of patients and add to the understanding of the safety profile of CAR-T.
REC name
South West - Frenchay Research Ethics Committee
REC reference
23/SW/0061
Date of REC Opinion
22 May 2023
REC opinion
Favourable Opinion